Form 4: Voyager Therapeutics Chief Legal Officer Jacquelyn Fahey Sandell Reports Stock and Option Awards

Jacquelyn Fahey Sandell, Chief Legal Officer of Voyager Therapeutics, reports the acquisition of stock and option awards.

Summary

• On February 21, 2025, Jacquelyn Fahey Sandell, Chief Legal Officer of Voyager Therapeutics, acquired 41,500 shares of common stock in the form of restricted stock units (RSUs) and options to purchase 83,000 shares of common stock.
• The RSUs vest over three years, with one-third vesting annually starting February 21, 2026, subject to continued service.
• The stock options, with an exercise price of $4.22, vest over four years, with 1/48th vesting monthly starting March 21, 2025, subject to continued service.
• Following these transactions, Sandell directly owns 123,143 shares of Voyager Therapeutics common stock and options to purchase 83,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, indicating confidence in the company's future.

Positives

• The grant of RSUs and stock options aligns the Chief Legal Officer's interests with those of the shareholders.
• The vesting schedules encourage continued service and commitment to Voyager Therapeutics.

Industry Context

Stock option and RSU grants are common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity compensation packages for Chief Legal Officers in biotech companies typically include a mix of stock options and restricted stock units.
• Vesting schedules of three to four years are standard in the industry to ensure long-term commitment.
• Comparable companies such as BioMarin, Sarepta Therapeutics, and Alnylam Pharmaceuticals also utilize similar equity compensation strategies.

Stakeholder Impact

• The equity grants align the executive's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates